Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer
The current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined with durvalumab consolidation therapy. However, radiotherapy ...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Mai Sakagami, Haruo Inokuchi, Nobutaka Mukumoto, Hiroshige Itoyama, Nobunari Hamaura, Mutsumi Yamagishi, Naoki Mukumoto, Shogo Matsuda, Daijiro Kabata and Keiko Shibuya Tags: Research Source Type: research
More News: Cancer | Cancer & Oncology | Interstitial Lung Disease | Lung Cancer | Non-Small Cell Lung Cancer